💊 Zydus Lifesciences Extends Rally After USFDA Nod for Key Drug

continued its upward momentum for a third straight session on 26 November 2025, trading over 1.4% higher by early afternoon. The sentiment remained positive after the company received final USFDA approval for its Verapamil Hydrochloride extended-release tablets in multiple strengths. The medication is widely used for blood-pressure management, and the approval strengthens Zydus’s presence in the US generics market. Investors cheered the news as it adds to the company’s pipeline potential and supports revenue growth prospects. The consistent uptrend reflects growing confidence in Zydus’s regulatory progress and product expansion strategy, keeping the stock firmly in demand throughout the day.